<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694001</url>
  </required_header>
  <id_info>
    <org_study_id>INSPIRE</org_study_id>
    <nct_id>NCT04694001</nct_id>
  </id_info>
  <brief_title>Evaluation of the Use of the Atalante Exoskeleton in Patients Presenting an Hemiplegia Due to Cerebrovascular Accident</brief_title>
  <acronym>INSPIRE</acronym>
  <official_title>Evaluation of the Use of the Atalante Exoskeleton in Patients Presenting an Hemiplegia Due to Cerebrovascular Accident</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wandercraft</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wandercraft</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The INSPIRE study is interventional, European, prospective, open, multicentric, each patient&#xD;
      being his/her own control.&#xD;
&#xD;
      It is conducted to assess the safety and performance of the Atalante exoskeleton system in&#xD;
      patients presenting an hemiplegia due to cerebrovascular accident. The primary endpoint is&#xD;
      defined by the reported adverse events.&#xD;
&#xD;
      The study will include 40 patients and takes place in six rehabilitation centers (4 in&#xD;
      France, 1 in Luxembourg, 1 in Belgium).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to evaluate the incidence of treatment-emergent adverse events.</measure>
    <time_frame>Throughout study completion, an average of 6 days</time_frame>
    <description>The primary endpoint is measured through reported Adverse Events (AEs) including adverse events (AEs), adverse device effects (ADEs), serious adverse events (SAEs), serious adverse device effects (SADEs), adverse procedure effects (APE), and new findings (NFs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the patient's ability to walk without the Atalante exoskeleton</measure>
    <time_frame>At study start, day 1 and at study completion, up to 6 days</time_frame>
    <description>Evaluation of the walk performance with the Functional Ambulation Category (FAC) at baseline and session 6 (from 0 to 5, 0 being &quot;patient cannot walk&quot; and 5 &quot;patient can walk independently anywhere&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the patient's gait speed without the Atalante exoskeleton</measure>
    <time_frame>At study start, day 1 and at study completion, up to 6 days</time_frame>
    <description>Evaluation of the gait speed measured without the Atalante exoskeleton in 10MWT at baseline and session 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the patient's endurance without the Atalante exoskeleton</measure>
    <time_frame>At study start, day 1 and at study completion, up to 6 days</time_frame>
    <description>Evaluation of the covered distance without the Atalante exoskeleton measured in 6MWT at baseline and session 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the patient's static and dynamic balance without the Atalante exoskeleton</measure>
    <time_frame>At study start, day 1 and at study completion, up to 6 days</time_frame>
    <description>Evaluation of static and dynamic balance without the Atalante exoskeleton measured with the Berg Balance Scale at baseline and session 6 (0-20 on the BBS represents balance impairment; 21-40 on the BBS represents acceptable balance; 41-56 on the BBS represents good balance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the patient's spasticity</measure>
    <time_frame>At study start, day 1 and at study completion, up to 6 days</time_frame>
    <description>Evaluation of the spasticity of the adductor muscles, hamstrings, quadriceps, and triceps surae measured with Modified Ashworth Scale at baseline and session 6&#xD;
0 No increase in muscle tone&#xD;
Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM&#xD;
More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved&#xD;
Considerable increase in muscle tone, passive movement difficult&#xD;
Affected part(s) rigid in flexion or extension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the patient's pain</measure>
    <time_frame>At study start, day 2 and at study completion, up to 6 days</time_frame>
    <description>Evaluation of the pain measured before and after sessions 1 to 5 using the Visual Analogical Scale-Pain.&#xD;
The patient is asked to make pain ratings between &quot;No Pain&quot; and &quot;Maximum pain imaginable&quot;, , with &quot;No pain&quot; corresponding on 0 on the caregiver side and and &quot;Maximum pain imaginable&quot; to 10 on caregiver side.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the patient's capability to stop the exoskeleton on time using the remote</measure>
    <time_frame>At study mid term, up to 5 days</time_frame>
    <description>Evaluation of the patient's capability to stop the exoskeleton, on time using the remote at session 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the patient's satisfaction and perceptions upon completion of a locomotor training program with the Atalante exoskeleton</measure>
    <time_frame>At study completion, up to 6 days</time_frame>
    <description>Evaluation of the satisfaction et perceptions via a questionnaire specific to the use of robotics exoskeleton at session 6.&#xD;
Questions are answered on a 7-level Likert scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the use of the Atalante exoskeleton</measure>
    <time_frame>At study start, day 2 and at study completion, up to 6 days</time_frame>
    <description>Collection of data relating to the patient's walking parameters and level of assistance with the Atalante exoskeleton during sessions 1 to 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the patient's skin condition to monitore the pressure points the patient may have with the contact of the exoskeleton.</measure>
    <time_frame>At study start, day 2 and at study completion, up to 6 days</time_frame>
    <description>The operator will perform a visual monitoring of the patient's skin to identify potential cutaneous morbidity at pressure points the patient may have with the exoskeleton before and after sessions 1 to 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the patient's level of anxiety and depression</measure>
    <time_frame>At study start, day 1 and at one week afetr the study completion, up to 12 days</time_frame>
    <description>Assessment of patient anxiety and depression by means of the Hospital Anxiety and Depression (HAD) scale at baseline and one week after the 5th session</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Stroke</condition>
  <condition>Stroke, Acute</condition>
  <condition>Stroke, Subacute</condition>
  <condition>Chronic Stroke</condition>
  <arm_group>
    <arm_group_label>Hemiplegia due to Cerebrovascular Accident (CVA)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Use of the Atalante exoskeleton</intervention_name>
    <description>A session includes stand-up, walks, exercises with or without the assistance of the exoskeleton, rotation, side and back step, squat and sitting.</description>
    <arm_group_label>Hemiplegia due to Cerebrovascular Accident (CVA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with hemiplegia due to cerebrovascular accident, occurred two weeks ago or&#xD;
             more, follow up in a rehabilitation center or in a hospital (inpatient or outpatient),&#xD;
&#xD;
          -  Patient presenting a FAC score of 0, 1, 2 or 3,&#xD;
&#xD;
          -  Patient whose etiological evaluation of the stroke has been complete,&#xD;
&#xD;
          -  Adult patient â‰¥18 years old,&#xD;
&#xD;
          -  Patient able to read and write in at least one of the languages of the country and who&#xD;
             have signed an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with severe spasticity of adductor muscles, hamstring, quadriceps and&#xD;
             triceps surae. Severe spasticity is defined by a score greater than 3 on the modified&#xD;
             Ashworth scale,&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Individuals with history of osteoporotic fracture and pathology or treatment causing&#xD;
             secondary osteoporosis,&#xD;
&#xD;
          -  Pressure Ulcer of Grade I or higher according to the NPUAP International Pressure&#xD;
             Ulcer Classification System- EPUAP, in areas of contact with the Atalante system,&#xD;
&#xD;
          -  Severe aphasia limiting ability to express needs or to fulfil questionnaires, at the&#xD;
             discretion of the physician.&#xD;
&#xD;
          -  Patient with a cardiac or respiratory contraindication to physical exertion,&#xD;
&#xD;
          -  Patient with a score below 18 on the Mini Mental State test,&#xD;
&#xD;
          -  Patient unable to deliver his/her consent,&#xD;
&#xD;
          -  Patient under legal protection,&#xD;
&#xD;
          -  Patient participating at the same time in another study,&#xD;
&#xD;
          -  Patients with morphological contraindications to the use of the Atalante exoskeleton.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rebecca Sauvagnac, Dr</last_name>
    <phone>(0)179353109</phone>
    <phone_ext>+33</phone_ext>
    <email>rebecca.sauvagnac@wandercraft.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pauline Beaumel</last_name>
    <phone>(0)179353109</phone>
    <phone_ext>+33</phone_ext>
    <email>pauline.beaumel@wandercraft.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Thierry Lejeune</last_name>
      <phone>(0)27641648</phone>
      <phone_ext>+32</phone_ext>
      <email>thierry.lejeune@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jacques CalvÃ© - Fondation Hopale</name>
      <address>
        <city>Berck</city>
        <zip>62600</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Gabriel PrÃ©vinaire</last_name>
      <phone>(0)321892020</phone>
      <phone_ext>+33</phone_ext>
      <email>jean.previnaire@hopale.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de MÃ©decine Physique et de RÃ©adaptation</name>
      <address>
        <city>Pionsat</city>
        <zip>63330</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Soultana Tatsidou</last_name>
      <phone>(0)473856364</phone>
      <phone_ext>+33</phone_ext>
      <email>s.tatsidou@apajh.asso.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre mutualiste de RÃ©Ã©ducation et de RÃ©adaptation de Kerpape</name>
      <address>
        <city>Ploemeur</city>
        <zip>56270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacques Kerdraon</last_name>
      <phone>(0)297826060</phone>
      <email>jkerdraon@kerpape.mutualite56.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital La Musse, La Renaissance Sanitaire</name>
      <address>
        <city>Saint-SÃ©bastien-de-Morsent</city>
        <zip>20119</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Hafid Boubkry</last_name>
      <phone>(0)232293031</phone>
      <phone_ext>+33</phone_ext>
      <email>h.boubkry@hlrs-lamusse.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rehazenter</name>
      <address>
        <city>Luxembourg</city>
        <zip>2674</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <contact>
      <last_name>Thierry Debugne</last_name>
      <phone>2698 - 4107</phone>
      <phone_ext>+352</phone_ext>
      <email>thierry.debugne@rehazenter.lu</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Robotics</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Physiotherapy</keyword>
  <keyword>Powered exoskeleton</keyword>
  <keyword>Walking</keyword>
  <keyword>Exercises</keyword>
  <keyword>Ambulation</keyword>
  <keyword>Stroke</keyword>
  <keyword>Acute stroke</keyword>
  <keyword>Subacute stroke</keyword>
  <keyword>Chronic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Hemiplegia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

